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There are limited data on circulating, cell-free, tumour (ct)DNA analysis in locally advanced rectal cancer 
(LARC). Digital droplet (dd)PCR was used to investigate KRAS/BRAF mutations in ctDNA from baseline 
blood samples of 97 LARC patients who were treated with CAPOX followed by chemoradiotherapy, 
surgery and adjuvant CAPOX ± cetuximab in a randomised phase II trial. KRAS mutation in G12D, G12V 
or G13D was detected in the ctDNA of 43% and 35% of patients with tumours that were mutant and 
wild-type for these hotspot mutations, respectively, according to standard PCR-based analyses on 
tissue. The detection rate in the ctDNA of 10 patients with less common mutations was 50%. In 26 cases 
ctDNA analysis revealed KRAS mutations that were not previously found in tissue. Twenty-two of these 
(84.6%) were detected following repeat tissue testing by ddPCR. Overall, the ctDNA detection rate in 
the KRAS mutant population was 66%. Detection of KRAS mutation in ctDNA failed to predict prognosis 
or refine patient selection for cetuximab. While this study confirms the feasibility of ctDNA analysis in 
LARC and the high sensitivity of ddPCR, larger series are needed to better address the role of ctDNA as 
a prognostic or predictive tool in this setting.
Screening for tumour genetic alterations is a standard procedure in modern oncology. Analysis of biopsy and/
or resection specimens is routinely performed in many cancers in an attempt to identify molecular abnor-
malities that can provide useful diagnostic, prognostic or predictive information and assist clinicians in the 
decision-making process.
Nevertheless, it has been increasingly recognised that tissue-based genetic tests are limited by some inherent 
characteristics of cancer such as intra-tumour heterogeneity and clonal evolution1. Tumour lesions are composed 
of clones of cancer cells that may differ in terms of genetic make-up and aggressive potential. The relative contri-
bution of each clone to the overall tumour phenotype and disease burden at a given time is also largely affected by 
a number of factors including exposure to treatments that exert a selective pressure on cancer cells and ultimately 
drive tumour evolution2. Therefore, genetic analyses on pre-existing archived tissue and/or random sampling of 
small amount of tumour may result in a suboptimal portrayal of the tumour molecular profile and be of limited 
value in routine practice.
Over the last few years, detection and analysis of circulating, cell-free, tumour DNA (ctDNA) in the blood 
has emerged as an alternative analytic method with the potential to overcome the above limitations and provide 
a real-time, exhaustive characterisation of cancer genome3. Although the exact mechanisms whereby cancer cells 
shed DNA into the bloodstream have not been fully elucidated, it is now clear that a simple blood sample (i.e., liq-
uid biopsy) is a valuable source of genetic material likely to encompass the wide intra- and inter-lesional tumour 
heterogeneity4. Compared with conventional, tissue-based, sampling procedures, blood sampling is quicker, 
less invasive and by far more convenient for both patients and clinicians/health providers. All these advantages 
make liquid biopsy also particularly suitable for the dynamic assessment of tumour response to treatment or 
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monitoring of disease status during follow-up5–7. The clinical usefulness of ctDNA analysis is confirmed by the 
recent approval by the Food and Drug Administration of the cobas EGFR Mutation Test v2 as a blood-based diag-
nostic tool for the detection of epidermal growth factor receptor (EGFR) mutations and selection of non-small 
cell lung cancer patients who are candidates for erlotinib treatment8. Also, algorithms have been proposed for 
non-invasive diagnosis and discrimination of cancer type based on copy number variation in ctDNA9.
In colorectal cancer, detecting and quantifying ctDNA by using common somatic mutations (i.e., APC, TP53, 
KRAS) and/or tumour epigenetic alterations (i.e., CDKN2A or RASSF2A methylation) has been demonstrated 
to be feasible and clinically relevant. Studies have reported an association between presence of post-operative 
ctDNA and risk of tumour recurrence in early-stage colon cancer10–12 or presence/levels of ctDNA and over-
all tumour burden/prognosis in metastatic patients13,14. Moreover, tracking KRAS mutations and other genetic 
aberrations accounting for primary or secondary resistance to anti-EGFR monoclonal antibodies is an attractive 
dynamic method to monitor the emergence/evolution of resistant clones to cetuximab or panitumumab and to 
potentially allow the implementation of adaptive treatment strategies4,15–17.
Nevertheless, limited information is available on the feasibility and clinical potential of ctDNA analysis in 
non-metastatic rectal cancer. Algorithms for risk stratification have been recently developed for these patients 
and risk-adapted therapies increasingly investigated in clinical trials and ultimately implemented in routine prac-
tice18–20. It is possible that, in this setting, the analysis of ctDNA may provide valuable information to combine 
with standard clinico-pathological and imaging data and lead to a better assessment of individual patient risk 
and more refined treatment approaches. Only a few studies have been conducted so far in rectal cancer patients 
who were treated with neoadjuvant chemoradiotherapy and surgery21–24. The results of these studies are dif-
ficult to interpret and compare especially due to the small numbers and significant heterogeneity with regard 
to the methods used for the assessment of ctDNA (i.e., total circulating cell-free DNA, DNA integrity index or 
tumour-specific molecular alterations) and the outcome measures selected for the evaluation of tumour response 
to treatment (i.e., pathological downstaging or tumour regression grading).
Therefore, we aimed to contribute to the existing data around liquid biopsy in non-metastatic rectal cancer 
by assessing feasibility, hurdles and potential clinical implications of using KRAS/BRAF mutations as markers for 
ctDNA detection in a relatively large prospective series of locally advanced rectal cancer (LARC) patients who 
were included in a randomised phase II trial (EXPERT-C)25.
Material and Methods
Patients. EXPERT-C (Trial registration: ISRCTN Register: 99828560) was an international, multicenter, ran-
domised phase II trial in which patients with high-risk LARC were treated with 12 weeks of neoadjuvant chemo-
therapy with CAPOX (oxaliplatin 130 mg/m2 on day 1 and capecitabine 1700 mg/m2/day for 14 days, every 3 
weeks) followed by chemoradiotherapy (50.4 Gy in 28 fractions with concomitant continuous capecitabine 1650 
mg/m2/day over 6 weeks), total mesorectal excision (4 to 6 weeks after completion of chemoradiotherapy) and 
12 weeks of adjuvant CAPOX (as above) with or without weekly cetuximab (400 mg/m2 loading dose, 250 mg/m2 
subsequent doses)25. Randomisation was in a 1:1 ratio. Written informed consent was obtained from each patient 
before study entry.
In this study, the definition of high-risk locally advanced tumour was based on high-resolution MRI of the 
pelvis. Only patients who had at least one of the following high-risk features at baseline were considered eligi-
ble: depth of extramural spread ≥5 mm (i.e., so called T3c or T3d stage), T4 stage, T3 tumour at/below levator 
muscles, tumour within 1 mm of mesorectal fascia, or presence of extramural venous invasion (EMVI). Distant 
metastases were an exclusion criterion and ruled out with a CT scan of the thorax and abdomen. During treat-
ment, MRI and CT scans were repeated after completion of neoadjuvant chemotherapy and chemoradiotherapy 
with MRI scans being centrally reviewed by a blinded radiologist. Details regarding patient follow-up have been 
reported previously25.
Blood-based KRAS and BRAF mutation analysis. DNA was isolated from 2 ml of plasma collected 
prior to commencement of neoadjuvant treatment and analysed by digital droplet (dd)PCR (QX200 ddPCR sys-
tem, Bio-Rad, Berkeley, California) according to the manufacturer’s protocol. All PCR reactions were prepared 
using the ddPCR Supermix with no dUTTP for probes (Bio-Rad) and performed as duplex PCR using the rele-
vant digital PCR assays for the wild-type and the mutation in question. Droplets were generated using the QX200 
droplet generator. The PCR reaction was performed in a C1000 Touch Thermo Cycler (Bio-Rad) using the fol-
lowing protocol: 95 °C for 10 minutes followed by 40 cycles of 94 °C for 30 seconds and 55 °C for 1 minute, then 
98 °C for 10 minutes. Droplets were read in the QX200 droplet reader and analysed using the Quantasoft software 
version 1.6.6.0320 (Bio-Rad).
Due to the limited availability of plasma, only the most common KRAS (i.e., G12D, G12V and G13D) and 
BRAF (i.e., V600E) mutations were analysed in all assessable patients. Any additional, patient-specific, KRAS 
mutation which was previously detected in the tumour tissue was also analysed in the DNA extracted from the 
plasma. The percentage of mutant KRAS or BRAF alleles (i.e., fractional abundance) was calculated as the ratio 
of drops positive for the mutant allele to drops positive for the mutant allele plus drops positive for the wild-type 
allele. The sensitivity cut-off for the ctDNA detection assay was set at the lower limit of 0.02% mutant alleles as 
previously reported26.
Tissue-based KRAS/NRAS/BRAF mutation analysis. When this study was conducted, data on tumour 
KRAS, NRAS and BRAF status for all assessable patients were already available. DNA for these mutational anal-
yses was extracted from formalin-fixed, paraffin-embedded (FFPE) tissue sections from biopsy and/or resection 
samples (depending on tissue availability/quality) and analysed in a central laboratory using standard PCR-based 
techniques. All the analyses were performed by investigators who were blinded to the clinical data. KRAS (exon 2 
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and 3) and BRAF (V600E) mutations were prospectively analysed with the INFINITI platform (AutoGenomics, 
Vista, CA, US). NRAS (exon 3) mutations were screened for as part of the original translational sub-study using 
multiplex PCR. Finally, KRAS (exon 4) and NRAS (exon 2 and 4) mutations were retrospectively analysed 
bi-directional Sanger sequencing. All mutations detected were confirmed on an independent PCR and sequenc-
ing analysis. For the purpose of this analysis, tumours harbouring KRAS mutation in either baseline biopsy or 
post-treatment resection specimen were considered as KRAS mutant. Similar approach was used for NRAS and 
BRAF mutation.
Further to the results of the ctDNA analysis, ddPCR as described above was performed on the same DNA 
which was previously extracted for standard PCR-based techniques as well as on DNA which was extracted from 
different FFPE tissue sections (if available) in order to screen for KRAS mutations which were found in the plasma 
but not previously detected in the tissue.
All methods were carried out in accordance with the Human Tissue Act 2004. The study protocol including 
molecular analyses on tumour tissues and blood samples was approved by the Committee for Clinical Research 
at The Royal Marsden NHS Foundation Trust and the relevant Research Ethics Committee. Written informed 
consent was obtained from all subjects.
Statistical analysis. The primary endpoint of the EXPERT-C trial was complete response (CR, either patho-
logic or clinical) in patients with KRAS exon 2–3/BRAF wild-type tumours and the study was designed to detect a 
20% improvement with the addition of cetuximab (odds ratio 3.4, two-sided α of 5% and 80% power). Secondary 
endpoints included progression-free survival (PFS) and overall survival (OS)25.
The main objective of this analysis was to assess the proportion of patients with detectable ctDNA using 
somatic KRAS/BRAF mutations as detection markers. Other objectives included evaluation of the association 
between ctDNA, clinico-pathological characteristics and outcome in KRAS mutant patients and the impact of 
ctDNA detection in relation to the short- and long-term effects of cetuximab in the entire study population.
Potential biases in the selection of eligible patients for this retrospective study were investigated by comparing 
the distribution of known prognostic clinical variables and treatment allocation between patients included in 
the analysis and those excluded due to lack of suitable blood samples. χ2 test or Fisher’s exact test were used to 
investigate potential associations between patient groups and categorical variables whilst t-test or non-parametric 
equivalent tests were used for continuous variables. Analyses were mostly descriptive. CR was defined using the 
RECIST v1.1 criteria. PFS was measured from date of randomisation to date of first progression/relapse or death 
from any cause. OS was measured from date of randomisation to death from any cause. Patients without an event 
were censored at last date known to be alive. The Kaplan-Meier method was used to summarise the survival esti-
mates while the Cox proportional hazards model was used to compare the survival rates between patient groups 
with and without adjustment for the effect of covariates. The proportional hazards assumption was tested with 
the use of Schoenfeld residuals. Interaction tests were conducted to investigate whether a differential treatment 
effect (i.e., with or without cetuximab) was present for CR rate, PFS and OS within the patient groups analysed.
Results
Of 164 eligible patients who were randomised in the EXPERT-C trial, 97 (59%) were assessable for the analy-
sis of KRAS/BRAF mutations in ctDNA (Fig. 1). There were no statistically significant differences in terms of 
demographics or baseline patient/tumour characteristics between the assessable and non-assessable groups 
with the only exception of location of the primary tumour and nodal status as defined by high-resolution MRI 
(Supplementary Table 1). Outcome was also similar between the two groups with regard to CR rate [OR 0.91 
(95% CI: 0.40–2.06), p = 0.81], PFS [HR 1.21 (95% CI: 0.70–2.10), p = 0.50] and OS [HR 1.45 (95% CI: 0.78–
2.69), p = 0.24].
Information on the tissue KRAS/BRAF status was available for the majority of ctDNA assessable patients 
(i.e., 90/97, 93%; lack of samples in 4 cases, analysis failed in 3 cases). Overall, KRAS mutations were previously 
detected in 38 patients (42%). Twenty-eight had a mutation in codon G12D, G12V or G13D (31%). Less com-
mon KRAS mutations were found in 10 additional patients (i.e., G12C = 3, G12S = 3, G12A = 2, A146T = 2) 
(11%). Paired tumour samples were available in 42 cases and the concordance for KRAS status was 83% (25 KRAS 
wild-type and 10 KRAS mutant) while in 7 patients KRAS mutation was detected in the pre-treatment biopsy but 
not in the post-treatment resection specimen. Only 3 patients (3%) were found to have BRAF mutant tumours (in 
2 cases the mutation was detected in paired samples while in 1 case in the pre-treatment biopsy only).
Mutations in codon G12D, G12V or G13D were found in the ctDNA of 35/97 assessable patients (36%) and 
34/90 (38%) patients with known tissue KRAS status (Fig. 2). In 2 patients two mutations were found (i.e., G12D/
G13D and G12D/G12V). The median mutant allele frequency in ctDNA was 0.41% for G12D (range 0.02–5.88), 
0.46% for G12V (range 0.06–2.35) and 0.22% for G13D (range 0.04–4.07). While the frequency of G13D muta-
tion appeared similar between tissue and blood samples (i.e., 9% vs. 9%, p = 0.92), G12D mutations were detected 
more frequently (i.e., 26% vs. 12%, p = 0.02) and G12V less frequently (i.e., 3% vs. 10%, p = 0.06) in ctDNA com-
pared with tumour tissue. Mutation in codon V600E of the BRAF gene was found in the ctDNA of 2 patients (2%).
Table 1 shows the comparison of KRAS status between tissue and plasma samples of individual patients (anal-
ysis restricted to codon G12D, G12V and G13D). A mutation in any of these 3 codons was found in the ctDNA 
of 12/28 patients (43%) with KRAS mutant tumours. In 3 cases the mutation involved a different codon com-
pared with that which was previously detected in the tissue (Supplementary Table 2). In the group of 62 patients 
with KRAS wild-type tumours, plasma mutations in G12D, G12V or G13D were identified in 22 cases (35%). 
Of note, in 11 of these (50%) the absence of tissue KRAS mutation was previously confirmed in both baseline 
biopsy and resection samples (Supplementary Table 3). The concordance rate between tissue KRAS mutation 
analysis by standard PCR-based techniques and ctDNA analysis by ddPCR was 58% (52/90) and 54% (49/90) 
for the overall mutational status and specific mutations, respectively. Among the 10 patients with less common 
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Figure 1. Study flow diagram and tissue availability in the ctDNA assessable population.
Figure 2. Frequency of the most frequently mutated KRAS hotspot mutation (i.e., G12D, G12V and G13D) 
in tissue (a) and plasma (b) of patients who were assessable for the analysis of circulating tumour DNA (tissue 
KRAS status was unknown for 7/97 patients).
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KRAS mutation (G12C, G12S, G12A or A146T), the ctDNA detection rate was 50% (5/10). In 2 patients, a new 
mutation in G12D was found instead of, or in addition to, the mutation which was previously detected in the 
tumour tissue (Supplementary Table 4). When data on less common mutations were also considered, the con-
cordance rate between tissue KRAS mutation analysis by standard PCR-based techniques and ctDNA analysis by 
ddPCR was 56% (50/90) and 46/90 (51%), for the overall mutational status and specific mutations, respectively 
(Supplementary Table 5). BRAF mutation was detected in the ctDNA of 1 out of 3 patients with BRAF mutant 
tumours and in 1 additional patient with a KRAS mutant/BRAF wild-type tumour.
Overall, in 26 cases ctDNA analysis revealed a KRAS mutation that was not previously found in tumour tis-
sue (i.e., 22 patients previously classified as having KRAS wild-type tumours and 4 patients with KRAS mutant 
tumours who were found to have a different KRAS mutation in ctDNA). In some of these patients, the discrep-
ancy between the results of tissue and plasma mutational analysis could be partly explained by a number of 
factors such as low frequency of the mutant allele in plasma, limited tissue availability (i.e., only one sample avail-
able, either biopsy or resection) or low tumour infiltration in tissue specimens (Supplementary Tables 6 and 7). 
Nevertheless, when ddPCR was used to analyse the same DNA that was previously extracted from tissue and 
assessed by standard PCR-based techniques, 20 of these 26 apparently newly detected plasma mutations (77%) 
were also detectable in the tissue. For 5 of the 6 patients with still discordant results, additional DNA from FFPE 
sections derived from the same tissue block was available for ddPCR testing. Two of these patients were con-
firmed to have tumours harbouring a KRAS mutation for an overall concordance between tissue and plasma of 
84% (22/26) (Fig. 3). In the remaining 4 patients in whom no KRAS mutation was detectable in tissue, the median 
mutant allele frequency in plasma was 0.64 (range 0.09–1.10).
When the results of KRAS/BRAF tissue analysis by ddPCR were taken into account, 59 patients were found 
to have mutant tumours for either KRAS or BRAF (mutations being detected in 38 cases by standard PCR-based 
techniques while in 21 cases by ddPCR). In this population the ctDNA detection rate was 66% (39/59). In Table 2 
demographics and baseline characteristics of KRAS/BRAF mutant/ctDNA negative patients (n = 20) are com-
pared with those of KRAS/BRAF mutant/ctDNA positive patients (n = 39). No differences were observed between 
these groups with the only exception of MRI T stage at baseline (p = 0.01). In particular, 25% of patients in the 
ctDNA negative group had T3d/T4 tumours compared with 47% of patients in the ctDNA positive group. EMVI 
was observed in 74% of ctDNA positive versus 55% of ctDNA negative patients while tumour location above 
levator muscles was observed in 44% and 20% in ctDNA positive and negative patients respectively but none of 
these differences were statistically significant. The analysis of outcome measures showed no difference between 
ctDNA positive and ctDNA negative patients in terms of CR rate [i.e., 15.4% vs. 10%, OR 1.63 (95% CI: 0.30–
8.96), p = 0.57], PFS [HR 0.70 (95% CI: 0.29–1.70), p = 0.43] and OS [HR 0.78 (95% CI: 0.31–1.96), p = 0.60]. 
Adjustment for known prognostic clinical variables did not change the results.
Overall availability of biological samples for mutational analysis in the EXPERT-C trial (n = 164) was as fol-
lows: 90 patients (55%) were assessable in both tissue and plasma, 59 (36%) in tumour tissue only and 7 (4%) in 
plasma only. Eight patients (5%) were not assessable in either tissue or plasma. In an exploratory analysis, data 
on KRAS status in ctDNA were combined with previously obtained data on KRAS/NRAS status in tumour tissue 
and patient outcome assessed by presence/absence of these mutations. Demographics and baseline characteristics 
were well balanced between patients with mutant tumours (i.e., KRAS/NRAS mutation in tissue and/or KRAS 
mutation in blood, n = 92) and those with wild-type tumours (i.e., neither KRAS/NRAS mutation in tissue nor 
KRAS mutation in blood, n = 30). No differences between these groups were observed with respect to CR rate 
(i.e., 15.2% vs. 10.0%, OR 1.62 (95% CI: 0.43–6.05), p = 0.48), PFS [HR 0.90 (95% CI: 0.47–1.75), p = 0.77] and OS 
[HR 1.01 (95% CI: 0.47–2.14), p = 0.98]. Also, no interaction was observed between mutation status and outcome 
of cetuximab treatment for CR (p = 0.52), PFS (p = 0.59) and OS (p = 0.98). Among the 90 patients with available 
data on KRAS/NRAS status on tissue and KRAS status on plasma, 8 (9%) had at least 2 RAS mutations (i.e., 2 
mutations in 8 patients, 3 mutations in 1 patient). Of these, 5 experienced tumour recurrence following curative 
treatment, 2 were alive and disease-free at 5 years and 1 withdrew the study due to toxicity.
Discussion
While the potential application of ctDNA analysis in early stage colon cancer and advanced colorectal cancer has been 
increasingly reported, the clinical utility of liquid biopsy in the setting of non-metastatic rectal cancer has been so far 
the subject of limited investigation. To our knowledge only 4 small studies addressing this topic have been published.
Blood KRAS WT KRAS MUT Total
Tissue
  KRAS WT 40 (64.5%) 22 (35.5%)* 62 (63.9%)
  KRAS MUT 16 (57.1%) 12 (42.9%)** 28 (28.9%)
  KRAS UNK 6 (85.7%) 1 (14.3%) 7 (7.2%)
  Total 62 (63.9%) 35 (36.1%) 97 (100%)
Table 1. Comparison of KRAS status (analysis restricted to codon G12D, G12V and G13D) between paired 
tissue (analysed by standard PCR-based techniques) and plasma samples (analysed by ddPCR). *In 11 cases the 
absence of tissue KRAS mutation was previously confirmed in both baseline biopsy and resection samples. **In 
3 cases the KRAS mutation which was found in ctDNA involved a different codon compared with the KRAS 
mutation which was previously detected in the tissue. Abbreviations: WT: wild-type; MUT: mutant; UNK: 
unknown.
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By using a real time PCR technique Zitt et al. analysed the levels of circulating cell-free DNA in 26 patients 
who were treated with pre-operative, fluorouracil-based, chemoradiotherapy for cT3–4 mid-low tumours21. A 
reduction of DNA levels was observed after completion of chemoradiotherapy in all patients but neither baseline 
nor post-treatment DNA concentrations were predictive of pathological downstaging. A significant difference 
between responders (i.e., ypT0–2) and non-responders (i.e., ypT3–4) was found only after surgery (i.e., further 
decrease of DNA in responders but increase of DNA in non-responders, p = 0.006). In a larger study including 67 
patients with cT3-4 and/or N+ tumours, Agostini et al. showed that the circulating cell-free DNA integrity index 
(i.e., a ratio between long and short DNA fragments) was statistically significantly different between responding 
and non-responding patients (as defined by the degree of tumour regression according to the Mandard score) 
only after completion of fluoropyrimidine-based chemoradiotherapy (p = 0.0009) but not at baseline22. The 
DNA integrity index at this time point was also found to be the only independent predictive factor of response 
to neoadjuvant treatment in multivariate analysis. The potential of the DNA integrity index in this setting was 
confirmed by Sun et al. who showed an association between this parameter (both at baseline and after neoadju-
vant treatment) and pathological tumour regression grading according to the Dworak’s score in 34 patients who 
received an oxaliplatin-based chemoradiotherapy for cT3-4 and/or N+ rectal tumours23. Interestingly, while the 
rate of KRAS codon 12 mutation decreased with chemoradiotherapy in all patients with no difference between 
responders and non-responders, a higher rate of MGMT methylation at baseline was predictive of pathological 
response. Finally, in a recent report of 4 LARC patients whose ctDNA was tracked in serial blood samples by 
using two patient-specific chromosomal rearrangements, Carpinetti et al. showed an overall lack of correlation 
between normalisation of ctDNA and amount of residual disease in the surgical specimens after neoadjuvant 
chemoradiotherapy24. However, changes of ctDNA levels after surgery appeared to predict tumour recurrence.
The aims of our study were to confirm that ctDNA analysis is feasible in a population of non-metastatic rectal 
cancer patients, to assess KRAS/BRAF mutations as markers for ctDNA detection, and to explore potential clin-
ical implications of detectable KRAS mutations in ctDNA. For this purpose, we analysed a relatively large and 
homogeneous series of patients with MRI-defined, high-risk, LARC who were treated with an investigational 
strategy plus or minus cetuximab within a randomised phase II trial25. The results support the potential of ctDNA 
as biomarker for LARC based on a number of interesting findings. Also they highlight possible challenges for 
future prospective ctDNA-based studies in this setting.
By using a pragmatic approach and restricting our analysis to the three most common KRAS mutations in 
exon 2 in the overall study population and to less common, patient-specific KRAS mutations in selected cases, 
we initially found that ctDNA was detectable in approximately 40% of patients. Interestingly, the rate of KRAS 
Figure 3. Results of KRAS mutational analysis by standard PCR-based techniques and ddPCR in tissue and 
plasma.
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mutation in plasma did not appear much different between patients with KRAS wild-type and those with KRAS 
mutant tumours. Also, in some patients from the latter group, the analysis of ctDNA showed the presence of 
additional KRAS mutations that were not detected on tissue. These observations support the higher sensitivity of 
ddPCR compared with the standard PCR-based techniques that were originally used for tumour mutational anal-
ysis in our series27. Indeed, when tissue-derived DNA of patients with discordant results was assessed by ddPCR, 
high concordance for KRAS status (i.e., 85%) was observed between tissue and plasma. On the other hand, the 
lack of complete concordance between tissue and plasma (i.e., 15% of patients had KRAS mutation in plasma 
only) suggests the ability ctDNA analysis to provide a more comprehensive characterisation of tumour molecular 
profiling and minimise the impact of tumour heterogeneity/random tissue sampling on routine mutational test-
ing procedures. In support of this contention, in 2 out of 22 patients with concordant results, the KRAS mutation 
was found only after the analysis of DNA which was extracted from different FFPE tissue sections.
Generally, one of the main concerns regarding the use of highly sensitive techniques is the clinical significance 
of sub-clonal somatic mutations that occur at a low frequency and therefore would be below the detection thresh-
old of common diagnostic platforms which are used in routine practice. Studies in metastatic colorectal cancer, 
however, suggest that increasing the detection sensitivity for tumour KRAS mutations may actually refine patient 
selection for anti-EGFR monoclonal antibodies by identifying a higher proportion of patients who fail to respond 
to these agents28. Furthermore, detection of low-frequency KRAS mutant alleles in blood of patients treated with 
cetuximab or panitumumb may represent an early sign of expansion/emergence of tumour resistant clones, pre-
dict forthcoming clinical progression and warrant consideration of alternative treatment strategies to overcome 
resistance7,17. In this study, we could not demonstrate that refining the RAS wild-type population by taking into 
account the results of the ctDNA analysis had an impact on the overall effect of cetuximab. In line with our previ-
ous reports of this trial where patients were classified according to either KRAS exon 2–3/BRAF or extended RAS 
tissue mutational status25,29,30, adding cetuximab to chemotherapy and chemoradiotherapy did not significantly 
ctDNA neg (n = 20) ctDNA pos (n = 39)
p valueN % N %
Gender
Male 13 65 23 59 0.65
Female 7 35 16 41
Age
Median (IQR) 66.7 (55.5–74.4) 65.1 (59.2–68.6) 0.38
WHO PS
0 10 50 18 46
0.78
1–2 10 50 21 54
MRI T
T3a 1 5 0 0
0.01
T3b 1 5 6 15
T3c 13 65 15 38
T3d 0 0 10 26
T4a 4 20 3 8
T4b 1 5 5 13
MRI EMVI+
No 9 45 10 26
0.13
Yes 11 55 29 74
MRI CRM+
No 11 55 20 51
0.79
Yes 9 45 19 49
Tumour height
At/below lev 16 80 22 56
0.09
Above lev 4 20 17 44
MRI N status
N0 6 30 15 38
0.28N1 8 40 8 21
N2 6 30 16 41
Treatment arm
CAPOX 12 60 21 54
0.65
CAPOX-C 8 40 18 46
Table 2. Comparison of demographics and baseline characteristics between KRAS mutant/ctDNA negative 
patients (n = 20) and KRAS mutant/ctDNA positive patients (n = 39). Abbreviations: WHO: World Health 
Organisation; PS: performance status; MRI: magnetic resonance imaging; EMVI: extramural venous invasion; 
CRM: circumferential resection margin; lev: levator muscles.
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improve the outcome of wild-type tumours. It should be noted, however, that in the EXPERT-C trial the use of 
cetuximab was investigational and there is still no evidence that EGFR is a valuable therapeutic target for LARC. 
Furthermore, some of the limitations of this study (i.e., retrospective analysis and relatively small sample size) 
and the use of a multimodality treatment approach including radiotherapy may have introduced significant biases 
and limited the ability to assess the role of either KRAS or RAS mutations as negative predictive biomarkers for 
cetuximab in this setting.
Despite the high sensitivity of ddPCR, more than one third of patients with KRAS/BRAF mutant tumours in 
our study were not found to harbour the corresponding mutation in plasma. One could argue that this may be 
partly explained by the decision to consider data from the analysis of resection specimens as representative of 
the tumour mutational status even in the absence of an assessable biopsy sample at baseline. However, the degree 
of concordance between paired specimens in our series was high and there was no case where the emergence 
of KRAS mutant clones following neoadjuvant treatment could be suspected. Furthermore, it is important to 
note that our data are in line with those previously reported in series of non-metastatic patients with colorec-
tal cancer or other tumour types11,31,32. Overall, this indicates that alternative strategies could be necessary to 
exploit the clinical potential of ctDNA analysis in larger populations. Although undetectable plasma KRAS/BRAF 
mutations could just reflect the absence of micrometastatic disease, ctDNA assays designed to detect multiple 
tumour-specific somatic aberrations may prove to be more sensitive and useful than those detecting single gene 
mutations (especially if present at a low allelic frequency). In this regard, it is interesting to note that, in our study, 
a difference between tissue and plasma was noted in terms of relative frequency of specific KRAS mutations. 
While this could be a random effect, it may also suggest that, at least in the setting of non-metastatic disease/
limited tumour burden, tumours with specific KRAS mutations (i.e., G12V) are less likely to release DNA in blood 
compared to those harbouring different mutations (i.e., G12D).
Although studies suggest that ctDNA analysis could be used as a minimally invasive, dynamic tool to predict 
prognosis and response to adjuvant treatment in localised colorectal cancer10–12, the results of our analysis do not 
appear to support this contention. In fact, even though an association between baseline poor-prognosis features 
and detectable ctDNA such as advanced T stage was found, there was no difference in outcome between patients 
with or without detectable ctDNA. It is possible, however, that this apparent discrepancy may be due to the 
timing of blood sampling (i.e., pre-operative in our study vs. post-operatively in other series) and the biological 
difference between detectable ctDNA at each of these time points. Furthermore, the treatment strategy used 
in the EXPERT-C trial with upfront administration of systemic chemotherapy might have limited the negative 
prognostic impact of ctDNA, this hypothesis being supported by the relatively low incidence of distant metastases 
observed in this trial and in other similar studies30,33.
Our study is the largest analysis of ctDNA in non-metastatic rectal cancer. It suffers, however, from a number 
of limitations such as the retrospective approach, the limited number of assessable patients and the use of detec-
tion techniques with different sensitivity in tumour tissue and plasma. Furthermore, the availability of only one 
blood sample per patient at baseline precluded the analysis of changes of ctDNA during/after neoadjuvant treat-
ment which are likely to be more informative in terms of assessment of treatment response and consideration of 
adaptive treatment strategies. Nevertheless, the data here reported confirm that KRAS/BRAF mutations in ctDNA 
can be detected by ddPCR with high sensitivity and provide further support for the initiation of prospective trials 
investigating the potential clinical applications of ctDNA analysis in the setting of LARC.
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